NCT03832855View on ClinicalTrials.gov

Assessing the Immunogenicity of pING-hHER3FL

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

July 13, 2020

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2030

Conditions

Advanced Cancer

Interventions

BIOLOGICAL

pING-hHER3FL

Plasmid vaccine containing HER3

Trial Locations (1)

27710

Duke University Medical Center, Durham

All Listed Sponsors

lead

Herbert Lyerly

OTHER